R

ecently published evidence that the world’s first licensed dengue vaccine poses a safety risk to people who have never before been infected with the disease has cast a chill over a critically important but risky field of vaccine development.

Several other dengue vaccines are in the pipeline. But problems with Sanofi Pasteur’s Dengvaxia are now generating questions about the others.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.